… The treatment effect of semaglutide versus placebo (unadjusted … of semaglutide on PCS
and MCS qualitatively did not change. … It does not specifically address CV outcomes, but it has …

… with overweight or obesity and pre-existing cardiovascular … secondary prevention population
without diabetes, both in terms … Mechanisms of cardiovascular risk reduction by semaglutide …

… on HF outcomes focused on patients with HF, in the … cardiovascular outcome trial of
subcutaneous semaglutide in patients with T2D and high cardiovascular risk (23.6% with HF)- no …

… diabetes and obesity to reduce CV risk (1,12). CV outcomes trials with GLP-1RAs, including
semaglutide, have demonstrated that these agents reduce CV risk and slow kidney function …

… In this analysis, CRP reduction was significantly greater with semaglutide compared with
placebo in the STEP 1 and 3 trials of people with overweight or obesity without diabetes. …

… cardiovascular disease and overweight or obesity but without diabetes, long-term semaglutide
… progression to biochemical diabetes but does not slow glycemic progression over time. …

… trials are investigating semaglutide as a new … obesity because greater WL was observed
with semaglutide than liraglutide ((21)). In the phase 2 trial of semaglutide in adults with obesity, …

… Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT)
cardiovascular outcome trial is examining whether once-weekly sc semaglutide 2.4 …

… The roles of semaglutide and dulaglutide, respectively, on EAT are also unknown. Hence, in
… weekly semaglutide and dulaglutide on EAT thickness in overweight/obese type 2 diabetics. …

… people with overweight or obesity with or without type 2 diabetes. Oral semaglutide 7 mg
and 14 mg once per day has been approved for the treatment of type 2 diabetes and improves …